Immunotherapy

 Identifying and treating autoimmune neurological disorders

Associate Professor Sudarshini Ramanathan is a neurologist and clinician scientist whose work focuses on autoimmune neurological disorders. Her research has helped identify new neurological syndromes due to antibody-mediated demyelination and encephalitis, and improve diagnostic tools and treatment guidelines for patients with autoimmune diseases affecting the brain, spinal cord, muscles and nerves. 

Vaccine effectiveness against infections triggering autoimmune disease

Dr Deborah Burnett is a Scientia Senior Lecturer and Laboratory Head at UNSW, where she leads a multidisciplinary research program spanning mechanistic immunology and translational vaccinology. Her work focuses on understanding how immune responses can protect against challenging infectious threats, including bacterial infections and infections associated with autoimmune disease.  

Pancreatic and lung cancers driven by mutations in the cancer gene KRAS

Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).

Development of novel analytical and diagnostic tools using nanotechnology and microfluidics

Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.

Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.

Next-generation NK cell-based immunotherapies for hard-to-treat cancers

Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.

Dr Jasmine Kaur

RESEARCH IN IMMUNOTHERAPY
@ GRIFFITH UNIVERSITY
QUEENSLAND, AUSTRALIA

Scroll to top